Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.169 - Monitoring of pulmonary function in pregnant women with severe asthma controlled in a monographic asthma and pregnancy unit
D1.154 - Mepolizumab treatment in a patient with severe eosinophilic granulomatosis with polyangiitis: a case report
D1.155 - Clinical, Functional and Inflammatory Characteristics of Young Adults with Bronchial Asthma Using Conventional Cigarettes, Electronic Nicotine Delivery Systems and Heated Tobacco Products
D1.156 - High relevance of upper airways comorbidities in T2 asthma inflammatory burden
D1.157 - Response to biologic therapy in severe asthma and chronic rhinosinusitis with nasal polyps according to nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity
D1.159 - Comorbidity of Asthma in Chronic Spontaneous Urticaria: Prevalence and Immunological Insights from a Sri Lankan Cohort
D1.160 - Perceptions, Attitudes, and Real-World Use of FENO in Allergy and Asthma Practice: Results of a National Survey from Türkiye
D1.161 - Clinical-epidemiological profile of pediatric difficult-to-control asthma in a tertiary referral center in Brazil
D1.164 - Evaluation of the use of cyclooxygenase-2 inhibitors in patients with AERD
D1.165 - Asthma Predisposition and miRNA Expression in Children with Recurrent Infections
D1.166 - REX-8756 is a First-in-Class Potent and Selective Orthosteric STAT6 Inhibitor That Demonstrates Efficacious Potential and Safety Differentiation in TH2-Mediated Inflammation
D1.168 - ASSOCIATION BETWEEN MOLECULAR ALLERGEN SENSITIZATION AND FeNO IN CHILDREN WITH ALLERGIC ASTHMA
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
Download the app
The congress at your fingertips
Available on
Download